Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 15 2019 - 5:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
FILE NUMBER: 001-36286
CUSIP
NUMBER: 00973E102
(Check
One):
|
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form
N-CSR
|
For
Period Ended:
March 31, 2019
|
[ ]
Transition Report on Form 10-K
|
|
[ ]
Transition Report on Form 20-F
|
|
[ ]
Transition Report on Form 11-K
|
|
[ ]
Transition Report on Form 10-Q
|
|
[ ]
Transition Report on Form N-SAR
|
For
the Transition Period Ended: ________________________
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
AKERS
BIOSCIENCES, INC.
Full
name of registrant:
N/A
Former
name if applicable:
201
Grove Road
Address
of principal executive office (Street and number):
Thorofare,
NJ 08086
City,
state and zip code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed
due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
Akers
Biosciences, Inc. (the “Company”) was unable, without unreasonable effort or expense, to file its Quarterly Report
on Form 10-Q for the period ended March 31, 2019 (“Form 10-Q”) by May 15, 2019, due to a delay experienced by the
Company in completing its financial statements. The Company anticipates that it will file the Quarterly Report no later than the
fifth calendar day following the prescribed filing date.
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
Howard
R. Yeaton
|
|
(856)
|
|
848-2116
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If the answer is no, identify report(s).
|
|
|
|
[X]
Yes [ ] No
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
|
[X]
Yes [ ] No
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
AKERS
BIOSCIENCES, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 15, 2019
|
By
|
/s/ Howard R. Yeaton
|
|
|
Howard R. Yeaton
|
|
|
Chief Executive Officer
|
INSTRUCTION.
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of
the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority
to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024